New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Bristol Myers Squibb Company

BMY

Healthcare Drug Manufacturers General

Bristol Myers Squibb Company’s revenue for fiscal 2025 (year ended December 2025) was $48.2 billion, roughly unchanged from fiscal 2024.

Revenue
+6.93%
EPS
−2.78%
Free cash flow
−36.0%
Total debt
−12.5%

Quarter to September 2026, against a year earlier

59.34 1.00 +1.71%
Market cap
$119.3B
P/E
12.9×
Fwd P/E FY26e
12.0×
Dividend yield
4.32%
F-score
8/9
ROIC
13.2%
Net debt / EBITDA
2.6×
Payout ratio
0.6×

Bristol Myers Squibb Company 10-Q filed Jul 31, 2025

Fiscal Q2 2025 · Period ended Jun 30, 2025 · Filed · accepted 12:17 PM ET · Document on sec.gov · Filing index

What changed

Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed Apr 24, 2025: 28 added · 11 removed · 56 modified; 11 with only figures updated

  1. Modified · EXECUTIVE SUMMARY

    During the first quarter of In 2025, we have achieved multiple regulatory approvals across our portfolio, including the: (i) approval of Breyanzi for Opdivo + Yervoy adults with relapsed or refractory FL in the EU , (ii) approval of Camzyos for the treatment of symptomatic obstructive HCM in Japan, (iii) approval of Opdivo + Yervoy as a first-line treatment of adult patients with unresectable or advanced hepatocellular carcinomaHCC in both the U.S. and the EU, (iiiv) approval for Breyanzi in the EU of Opdivo + Yervoy for first-line treatment of adults with relapsed or refractory FLand pediatric patients 12 years and (iii) approval for Camzyos for the treatment of symptomatic obstructive HCM older with unresectable or metastatic MSI-H or dMMR colorectal cancer in Japan. Additionallythe U.S., in April 2025, we achieved two approvals (v) approval of Opdivo as a perioperative regimen for Opdivo + Yervoy resectable high risk NSCLC in the U.S. for the treatmentEU and (vi) approval of adults and pediatric patients 12 years and older with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer and the treatment of adult patients Opdivo Qvantig for use across multiple adult solid tumors in the EU. Additionally, we received label updates from the FDA that have reduced or removed certain patient monitoring requirements associated with unresectable or metastatic hepatocellular carcinomathe use of Camzyos, Breyanzi and Abecma.